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Abstract
Ex vivo activation and expansion of lymphocytes for adoptive cell therapy has demonstrated great
success. To improve safety and therapeutic efficacy, increased antigen specificity and reduced non-
specific response of the ex vivo generated immune cells are necessary. Here, using a complete
protein-spanning pool of pentadecapeptides of the latent membrane protein 2A (LMP2A) of
Epstein-Barr virus (EBV), a weak viral antigen which is associated with EBV lymphoproliferative
diseases, we investigated the phenotype and function of immune effector cells generated based on
IFN-γ or CD137 activation marker selection and dendritic cell (DC) activation. These ex vivo
prepared immune cells exhibited a donor- and antigen-dependent T cell response; the IFN-γ-
selected immune cells displayed a donor-related CD4- or CD8-dominant T cell phenotype;
however, the CD137-enriched cells showed an increased ratio of CD4 T cells. Importantly, the
pentadecapeptide antigens accessed both class II and class I MHC antigen processing machineries
and effectively activated EBV-specific CD4 and CD8 T cells. Phenotype and kinetic analyses
revealed that the IFN-γ and the CD137 selections enriched more central memory T (Tcm) cells
than did the DC-activation approach, and after expansion, the IFN-γ-selected effector cells showed
the highest level of antigen-specificity and effector activities. While all three approaches generated
immune cells with comparable antigen-specific activities, the IFN-γ selection followed by ex vivo
expansion produced high quality and quantity of antigen-specific effector cells. Our studies
presented the optimal approach for generating therapeutic immune cells with potential for
emergency and routine clinical applications.
Background
The key to the success of immune cell therapy is to
increase specific and decrease non-specific immune
response. Ex vivo expanded antigen-specific T cells target-
ing cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
adenovirus have been successfully applied to treating
hematopoietic stem cell or solid organ transplant patients
who have developed post-transplant viral diseases. [1,2]
The labor-intensive and time-consuming process of isolat-
ing and expanding antigen-specific immune cells, how-
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ever, has hindered common practice of this medical
advent.
Donor leukocyte infusion has attained a response rate of
>50% in treating post-transplant infections or cancer
relapse of hematopoietic stem cell transplant (HSCT)
patients. [3-5] Non-specific leukocyte infusion, however,
may cause severe graft-versus-host disease (GvHD) with
high morbidity and mortality. Adoptive transfer of anti-
gen-specific T cell clones combined with clinical regimens
to increase immune cell homeostasis has illustrated high
response rate (50%) in melanoma patients. [6-8] While
the amplified T cell clones display increased antigen-spe-
cific effector functions, the ex vivo expansion process takes
longer than 4–6 weeks, which often results in terminal
differentiation of the T cells with reduced in vivo prolifer-
ation potential. [9]
A few approaches have been developed to directly isolate
antigen-specific immune cells, such as the use of MHC-
peptide multimers and selection of IFN-γ-secreting cells
with affinity-magnetic beads. [10-14] Recently, CD137
(4-1BB), a member of the tumor necrosis factor receptor
family, has been reported to be a suitable surface marker
for antigen-specific T cell isolation. [15] Although both
the IFN-γ and the CD137 selection methods generate only
a small number of immune effector cells, these cells may
be further expanded in culture to obtain more functional
cells. [12]
Detailed phenotype and functional characterizations of
these ex vivo prepared immune effector cells are necessary
to facilitate their clinical applications. Here, we refined
and compared three of the state-of-the-art immune effec-
tor cell preparation approaches, the IFN-γ and the CD137
selection methods for emergency preparation of therapeu-
tic cells, and a DC-immune cell coculture method for the
expansion of antigen-specific immune cells. We targeted
EBV using LMP2A pentadecapeptides as antigens because
EBV-associated lymphoproliferative disorders represent
one of the most severe problems in HIV/AIDS patients
and transplantation patients. The IFN-γ-selected cells
showed an increased ratio of CD4 or CD8 effector cell
population depending on the donor, whereas the CD137
selection method enriched a higher ratio of CD4 T cells
regardless of the donor's T cell dominance response. Both
of the rapid protocols yielded more central memory and
effector memory T cells than did the DC-activation
method. Our detailed side-by-side comparison concludes
that IFN-γ selection followed by ex vivo expansion repre-
sents the preferred method for the generation of antigen-
specific immune effector cells with potential for clinical
applications.
Methods
Peripheral blood mononuclear cells (PBMC) and B 
lymphoblastoid cell lines (BLCL)
Healthy donors' buffy coats were obtained from Civitan
Blood Center (Gainesville, FL, USA). PBMC were prepared
by gradient density centrifugation in Ficoll-Hypaque (GE
Healthcare Bio-Sciences AB, NJ, USA) as previously
described. [16] Viability was determined by trypan blue
staining. Autologous B lymphoblastoid cell line (BLCL)
was generated by transforming peripheral blood B lym-
phocytes with EBV as described previously. [17] The BLCL
were continuously propagated in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 100 μg/ml strep-
tomycin, 100 IU/ml penicillin and 10% heat inactivated
fetal bovine serum (FBS) at 37°C with 5% CO2.
Peptides
The mixtures of 11 amino acid overlapping pentade-
capeptides (122 peptides) spanning the entire 497 amino
acids (NCBI Accession number P13285) of LMP2A of the
EBV (human herpesvirus 4, strain B95-8) and the Wilms'
tumor antigen (WT1, 449 amino acids, 110 peptides)
were purchased from JPT Peptide Technologies GmbH
(Berlin, Germany).
Preparation of 2 day and 5 day dendritic cells (DC)
PBMC were plated into 6-well plate at 1 × 107 cells/well
and adhered for 2 hours in AIM-V (Gibco-BRL, CA, USA).
The non-adherent cells were removed gently and frozen as
source of lymphocytes for co-culture use. Adherent mono-
cytes were cultured in AIM-V supplemented with 50 ng/ml
of GM-CSF and 25 ng/ml IL-4 (eBiosource International,
Inc. Camarillo, CA, USA). For the generation of 2 day DC,
the adherent cells were cultured with GM-CSF and IL-4 for
24 h and incubated for another 24 h with TNFα (50 ng/
ml), IL-1β (10 ng/ml), IL-6 (10 ng/ml, all from R&D sys-
tems, MN, USA) and PGE2 (1 uM, Sigma-Aldrich, MO,
USA) to induce maturation. For the generation of 5 day
DC, cells were cultured with GM-CSF and IL-4 for 5 days.
On day 3, half of the medium was replaced with fresh
medium containing GM-CSF and IL-4. On day 5, the
immature DC were induced into maturation with TNFα
(50 ng/ml), LPS (1 μg/ml, Sigma-Aldrich) and IFN-γ (50
ng/ml, R&D systems).
Isolation of antigen-specific IFN-γ secreting or CD137 
positive cells
PBMC were resuspended in AIM-V plus 5% human AB
serum at 1 × 107 cells/ml and mixed with pentadecapep-
tides for EBV-LMP2A (10 ug/ml), mouse anti-human
CD28 antibody (Ab, 1 ug/ml, eBioscience, San Diego,
USA) and human β2-microglobulin (1 ug/ml, Sigma) to
enhance antigen presentation and costimulation. The
cells were incubated in a 37°C humidified incubator for
3–13 hours. IFN-γ secreting cells were enriched with theJournal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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IFN-γ Catch Reagent and CD137 positive cells with PE-
conjugated monoclonal anti-CD137 Ab (clone 4B4-1),
followed by affinity isolation using anti-PE microbeads
according to the manufacturer's instruction (Miltenyi Bio-
tech Inc. Auburn, CA, USA).
Generation of DC-activated antigen-specific immune cells
DC-activated antigen-specific immune cells were gener-
ated as previously described. [16] In brief, mature 2 day
DC were loaded with LMP2A peptides (2.5 ug/ml) for 2 h
and irradiated (20 Gy, or 2,000 rads). The antigen-pulsed
DC were cocultured with autologous non-adherent PBMC
at a ratio of 1:20 in AIM-V with 5% human AB serum. On
day 3, half of the medium was replaced with fresh
medium supplemented with IL-2 (12.5 U/ml), IL-7 (5 ng/
ml) and IL-15 (20 ng/ml, all from Gentaur, Aachen, Ger-
many). Half of the medium was replaced with fresh
medium with cytokines every other day.
Multi-color flow cytometry
Mature DC were analyzed using a four-color panel of
monoclonal Ab including PE-anti-CD14, FITC-anti-HLA-
DR, PE-anti-CD86, APC-anti-CD1a, PE-anti-CD 83, APC-
anti-CD40 and FITC-anti-HLA-I (BD Biosciences, San
Jose, CA, USA), APC-anti-DC-SIGN and PE-cy7-anti-
CD11c (eBioscience), and incubated for 30 min at 4°C.
Isotype-matched antibodies were used for controls. The
Ab-labeled cells were washed twice with PBS containing
1% FBS and analyzed with FACSCaliber or FACSAria
using FACSDiva software (BD Biosciences) and Flowjo
software (Tree Star, Inc., Ashland, OR, USA). For memory
T cell analysis, the cells were stained with PE-anti-IFN-γ or
PE-anti-CD137, in combination with APC-anti-CD4
(clone RPA-T4), Pacific blue-anti-CD8 (clone RPA-T8),
FITC-anti-CD45RA (clone HI100), PE-cy7-anti-CCR7
(clone 3D12), Percp-cy5.5-anti-CD28 (clone 293, all
from BD Biosciences) and Alexa-fluo 750-anti-CD27
(clone O323, eBioscience) at 4°C for 30 min and washed
twice with PBS containing 1% FBS. The percentage of dif-
ferent T cell subsets was analyzed using FACSAria with
FACSDiva and Flowjo softwares.
Immune effector assays: CD107a degranulation and 
intracellular cytokine staining
These assay were performed as described. [18] Briefly, 2 ×
105 LMP2A-specific T cells were stimulated for 5 h in a 96-
well plate with irradiated (20 Gy) antigen-loaded autolo-
gous DC. Monensin A (Sigma-Aldrich) and FITC-conju-
gated Abs for CD107a or isotype matched Abs (BD
Pharmingen, San Diego, CA, USA) were added 1 hour
after stimulation and incubated for 5 hours. Cells were
then stained with Abs against CD4 and CD8 and fixed,
permeabilized with Cytofix/Cytoperm solution and
stained with Ab against IFN-γ (all from BD Pharmingen)
at 4°C for 20 min. Unrelated peptide group was included
as a negative control for spontaneous CD107a expression
and/or cytokine production.
Detection of peptide-specific CD8+ T cells by MHC 
multimer analysis
Peptide-major histocompatibility complex (MHC)-pen-
tamer conjugate specific for EBV-LMP2A/TYGPVFMCL
(HLA-A*2402 restricted) was purchased from Proim-
mune (Springfield, VA, USA). T cells were incubated with
PE-labeled peptide MHC-pentamer at room temperature
for 10 min, washed and stained with APC-anti-CD3 and
FITC-anti-CD8 Ab (BD Pharmingen) on ice for 30 min,
and analyzed using FACSAria. At least 1 × 105 events were
collected for each sample.
T cell proliferation assay with carboxy-fluorescein 
diacetate succinimidyl ester (CFSE) staining
The CFSE-based proliferation assay was performed as pre-
viously described [19]. Briefly, LMP2A-specific T cells
were washed and labeled with 1 uM CFSE (Molecular
Probes, Inc., Eugene, OR, USA). The labeled cells were
washed and plated into 96-well U-bottom wells at 1 × 105
cells per well. Autologous DC were loaded with peptides
(2.5 ug/ml) for 2 hours and irradiated (20 Gy). The irradi-
ated DC were added to the CFSE-labeled T cells at a ratio
of 1:20 and cultured in AIM-V with 5% human AB serum.
After 4 days, cells were harvested and analyzed with flow
cytometry.
Antigen-specific cytotoxicity assay of immune effector 
cells
The immune cell cytotoxicity assay was based on Jedema
et al. with minor modifications. [20] The target cells were
washed with PBS, and labeled with 1 uM CFSE (Molecular
Probes) at 5 × 106 cells per ml at 37°C for 15 minutes. The
reaction was stopped with the addition of 10 volumes of
complete RPMI containing 10% FCS, followed with a 30
min incubation at 37°C. After two washes, the CFSE-
labeled target cells were resuspended in AIM-V containing
5% human AB serum. The cell concentration was adjusted
to 1 × 105 cells/ml before plating into 96-well microtiter
plates at 100 ul/per well. The effector cells were then
mixed with target cells at a ratio of 1:1. The plates were
incubated in a humidified atmosphere of 5% CO2 and
37°C. The target cells included irradiated (20 Gy) autolo-
gous DC loaded with LMP2A peptides or control WT1
peptides, and irradiated (100 Gy) autologous BLCL. The
effector cells included LMP2A peptide-stimulated IFN-γ-
selected cells, LMP2A pulsed DC-expanded effector cells,
LMP2A peptide-stimulated IFN-γ-negative PBMC, and
control PBMC. After 6 hour of incubation, the cells were
mixed with 10,000 Flow-Count Fluorospheres (BD
Pharmingen) and followed by flow cytometry analysis. To
stain for dead cells, 7-AAD (10 ug/ml) was added and
incubated for 30 min on ice. For each sample, 5,000Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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microbeads were acquired, facilitating the calculation of
absolute numbers of target cells. The percentage of sur-
vival was determined as the following:
(R refers to different CTL ratio groups; R = 0 refers to the
CTL = 0 control)
Statistical analysis
Data were analyzed using GraphPad Prism 4 analysis soft-
ware (GraphPad Software Inc. San Diego, CA) and Stu-
dent's  t-test. A 2-sided P value of less than 0.05 was
considered statistically significant.
Results
Both IFN-γ and CD137 are effective markers for the 
isolation of antigen-specific immune effector cells
The small population of immune effector cells specific for
a particular antigen may be isolated based on expression
of antigen-specific activation markers. IFN-γ and CD137
have been identified as antigen-specific activation mark-
ers. Upon antigen stimulation, the IFN-γ secreting cells
can be captured with anti-IFN-γ Ab conjugated with an
anti-surface marker Ab. Alternatively, CD137 positive
cells can be directly isolated using anti-CD137 Ab. Spe-
cific T cell immune response to the peptide library span-
ning the entire LMP2A sequence has been previously
documented. [21] We first established the expression
kinetics of IFN-γ and CD137 in PBMC after stimulation
with a pool of EBV LMP2A pentadecapeptides, as reports
by others, the expression peaked at 6–12 hr for IFN-γ and
24 hr for CD137 (data not shown). [15,22] The IFN-γ- and
CD137-expressing cells were isolated using Ab-conju-
gated magnetic bead affinity columns (Miltenyi Biotech).
After examining a large number of donors, we found that
the antigen-specific response of an individual could be
either CD8 or CD4 T cell dominant, which can be donor-
and/or antigen-dependent. Representative results are
illustrated in Fig. 1A (a CD4-dominant donor to the left,
and a CD8-dominant donor to the right). The results indi-
cated that the CD4/CD8 ratio of the IFN-γ-selected cells
correlated with the donor's T cell dominance phenotype.
However, the CD137-enriched cells consistently showed
an increased CD4 to CD8 ratio regardless of the donor's
phenotype (Fig. 1A, bottom); the latter could be due to
the increased proportion of CD137 positive CD4 cells in
the total population of T cells before and after stimulation
(Fig. 1B). However, quantitative analysis of the expression
level of CD137 demonstrated that CD8 T cells expressed
higher density of surface CD137 than did CD4 T cells in
both CD4 and CD8 dominant individuals (see geometric
means in Fig. 1C).
The antigen-activated IFN-γ and CD137 positive immune 
cells display different surface phenotypes
The phenotype of the immune cells of the two affinity iso-
lation methods has not been characterized in the past due
to the limited number of the total harvested cells. We sub-
jected the IFN-γ- and CD137 affinity-purified cells to a
multi-color flow cytometry analysis for central memory
(Tcm, CCR7+, CD45RA-), effector memory (Tem, CCR7-,
CD45RA-), terminal effector (Teff, CCR7-, CD45RA+),
differentiation (CD27 and CD28) and migration (CCR7)
markers of T cells in addition to CD4, CD8 and IFN-γ (or
CD137). We found that there was a trend of increased
early-differentiated Tcm and Tem cells in the dominant
populations (Fig. 2A and 2B, CD4- and CD8-dominant
donors, respectively).
Ex vivo expansion of antigen-activated IFN-γ and CD137 
positive immune cells
To see if the enriched immune effector cells could be fur-
ther expanded, we cultured them on irradiated autologous
feeder PBMC; the cells expanded approximately 600-fold
in two weeks (not shown). Before expansion, the CD137
enriched cells contained a higher ratio of CD4 T cells (Fig.
1B, 37.6 vs. 13.1); however, the donor's dominant pheno-
type was restored after expansion in culture (Fig. 3A). Fur-
thermore, we consistently observed an increased
population of CD3-CD56+ cells in the CD137+ cell expan-
sion culture compared with the IFN-γ cell expansion cul-
ture (Fig. 3A top, 32.7% and 8.5% versus 2.3% and 2.6%,
for a CD4-dominant and a CD8-dominant donors,
respectively). Compared with the freshly isolated effector
cells that contained more memory effector cells (Fig. 2),
the cultured cells differentiated toward Tem and (Teff)
cells after expansion (Fig. 3B and 3C). Intracellular stain-
ing for effector cytokines showed that the expanded IFN-γ
and CD137 cells displayed high antigen-specific activities,
up to 59% and 34% for IFN-γ and CD137 selected cells,
respectively, when restimulated with DC-pulsed with the
specific antigens (LMP2A petadecapeptides) or autolo-
gous EBV positive BLCL (Fig. 4A and 4B, control: WT-1
peptide-pulsed DC). To demonstrate antigen-specific
cytolytic activity, we incubated these cells with different
target cells as illustrated in Fig. 4C. The effector cells killed
specific target cells with high specificity including autolo-
gous BLCL and LMP2A peptide-pulsed DC, but not con-
trol WT-1 peptide-pulsed DC (Fig. 4C, effector to target
ratio 1:1).
Ex vivo expansion of antigen-specific immune effector 
cells with dendritic cells (DC)
Antigen-specific immune effector cells can also be gener-
ated through DC activation. The latter protocol includes a
DC preparation step, followed by antigen exposure and
lymphocyte coculture. For the preparation of DC, we
compared the 2 day and the 5 day protocols. [23] We ana-
%
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lyzed the surface markers for plastic-adherent monocytes
and mature DC with flow cytometry (data shown in Addi-
tional file 1), and analyzed phenotypes of the 2 day and
the 5 day mature DC (Fig. 5). The 2 day DC expressed
higher levels of class I/II MHC (HLA-I and HLA-DR), cos-
timulatory molecules (CD86 and CD40) and maturation
marker CD83. We also found that the 2 day DC induced
primary and secondary immune response against viral or
cancer antigens at efficiencies equal to or better than the 5
day DC (manuscript in preparation). Therefore, the 2 day
DC protocol was adopted for later experiments.
The 2 day DC were pulsed with the pooled LMP2A penta-
decapeptides, irradiated and cocultured with autologous
lymphocytes at a ratio of 1:20. The cell number usually
decreases around day 5 after coculture, followed by an
increase of a few fold around day 17, suggesting a loss of
non-specific cells followed by expansion of antigen-spe-
cific cells (see representative growth curves in Fig. 6A).
Flow cytometry analysis of the DC-activated cells in cul-
ture from four different donors at day 0, 12 and 19 indi-
cated that most donors generated CD3+CD56- T cells, but
some generated a large proportion of CD3-CD56+ NK
cells and CD3+CD56+ cells (e.g. donor 3, Fig. 6B). The
relative ratios of CD4+ T cells, CD8+ T cells, NK cells and
CD3+CD56+ cells in the coculture appeared to be donor-
dependent (Fig. 6B and 6C). Furthermore, phenotype
analysis with multi-color flow cytometry demonstrated
IFN-γ- or CD137-based enrichment of antigen-specific immune effector cells Figure 1
IFN-γ- or CD137-based enrichment of antigen-specific immune effector cells. (A) CD4 and CD8 T cell distribution 
in IFN-γ- or CD137-positive cell population after antigen stimulation. The ratios of CD4 to CD8 T cells of five donors were 
presented. (B) and (C) CD137 expression in CD4 and CD8 T cells before and after Ab affinity column purification. PBMC were 
mixed with EBV LMP2 pentadecapeptides and 3–24 hr later, IFN-γ-secreting cells or CD137-positive cells were isolated by 
using MACS magnetic bead affinity columns as described in Materials and Methods. The cells were stained with PE-conjugated 
anti-IFN-γ or anti-CD137 Ab and CD3, CD4 and CD8 specific Ab and analyzed with flow cytometry.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Phenotype analysis of IFN-γ- or CD137-selected antigen-specific immune cells Figure 2
Phenotype analysis of IFN-γ- or CD137-selected antigen-specific immune cells. PBMC were stimulated with EBV 
LMP2A pentadecapeptides and IFN-γ or CD137 positive cells were isolated for analysis. (A) & (B) Memory and effector pheno-
type analysis based on seven-color flow cytometry with surface staining for CD27, CD28, CD45RA, CCR7, CD4, CD8, CD137 
and intracellular staining for IFN-γ immediately after cell isolation without further culture. The percentage of different popula-
tions (IFN-γ or CD137 plus CD4 or CD8 gated) of T cells is illustrated for a CD4-dominant donor (A) and a CD8-dominant 
donor (B); Tcm, central memory T cells (CD27+/-, CD28+, CCR7+, CD45RA-); Tem, effector memory T cells (CD27+/-, 
CD28+/-, CCR7-, CD45RA-); Teff, terminal effector T cells (CD27-, CD28-, CCR7+/-, CD45RA+).Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Phenotype analyses of IFN-γ- or CD137-selected immune effector cells after ex vivo expansion Figure 3
Phenotype analyses of IFN-γ- or CD137-selected immune effector cells after ex vivo expansion. (A) Phenotype 
analysis after ex vivo expansion. After the rapid selection, the antigen-specific immune cells were cultured for fifteen days with 
irradiated autologous PBMC as feeder cells. The distribution of CD3, CD4, CD8 and CD56 cell populations was determined 
and representative FACS graphs are shown. (B) and (C) Memory and effector phenotype analysis based on seven-color flow 
cytometry with surface staining for CD27, CD28, CD45RA, CCR7, CD4, CD8, CD137 and intracellular staining for IFN-γ. 
Representative results of a CD4-dominant donor (B) and a CD8-dominant donor (C) are shown.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Effector function analyses of IFN-γ- or CD137-selected immune effector cells after ex vivo expansion Figure 4
Effector function analyses of IFN-γ- or CD137-selected immune effector cells after ex vivo expansion. (A) and (B) 
Flow cytometry analysis of IFN-γ and CD137 expression after restimulation of the culture expanded IFN-γ or CD137 effector 
cells. The cells were restimulated with different cells as indicated and subjected to antibody staining and flow cytometry analy-
sis; control, WT-1 peptide-pulsed DC; specific, LMP2A peptide-pulsed DC; BLCL, autologous EBV-transformed B cells. (C) 
Analysis of antigen-specific cytolytic activity. The ex vivo expanded IFN-γ- or CD137-enriched cells were incubated with autol-
ogous EBV transformed B cells (BLCL), mature DCs loaded with either LMP2A pentadecapeptides (DC-LMP2A) or WT1 pen-
tadecapeptides (DC-WT1, as control) at 1:1 ratio in a cytotoxicity assay based on CFSE labeling as described in Materials and 
Methods.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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that the ex vivo expanded cells contained mostly Tem and
Teff cells (Fig. 7A and 7B, representative of CD4- and
CD8-dominant donors).
The DC-activated immune cells display antigen-specific 
effector functions
We next evaluated the DC-activated immune cells for anti-
gen-specific effector functions based on intracellular
staining of IFN-γ, IL-2, and the degranulation marker
CD107a after restimulation with peptide-loaded DC (Fig.
8A). For direct comparison, the same donor whose cells
were analyzed for the IFN-γ-selected effector functions
(Fig. 4B) was chosen. Analyses of the immune effector
cells without further stimulation (IE cell alone), or stimu-
lated with non-specific peptides (Non-specific) or with
the LMP2A pentadecapeptides (LMP2A-specific) demon-
strated LMP2A-specific expression of IFN-γ, IL-2 and
CD107a in the CD8 T cells, and to a lesser extent, the CD4
T cells (Fig. 8A top: IL-2 and IFN-γ, and bottom: CD107a
and IFN-γ). The antigen-specific effector function was fur-
ther confirmed with the CFSE-based proliferation assay, as
well as MHC-peptide pentamer specific for the LMP2A
epitope-specific T cell receptors of the CD8 T cells (data
not shown).
To demonstrate antigen-specific killing, we directly com-
pared the DC-activated cells to the IFN-γ captured cells (as
shown in Fig. 4C) using an in vitro cytolytic assay (Fig. 8B).
At an effector to target cell ratio of 1:1, the immune cells
effectively killed autologous BLCL and LMP2A-pulsed DC
(DC-LMP2A), but not DC pulsed with control WT1 pen-
tadecapeptides (DC-WT1). Therefore, effector function
Phenotype comparison of 5 day versus 2 day mature DC Figure 5
Phenotype comparison of 5 day versus 2 day mature DC. Surface markers related to antigen presentation function 
were stained with multi-color fluorochrome-labeled Ab and analyzed with FACSAria. Data represent MFI of mature DC gener-
ated from three healthy donors with p value calculated.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Ex vivo expansion and phenotype analyses of DC-activated immune effector cells Figure 6
Ex vivo expansion and phenotype analyses of DC-activated immune effector cells. EBV LMP2A-specific effector T 
cells were generated by stimulation of non-adherent PBMC with DC pulsed with LMP2A pentadecapeptides. (A) Growth 
kinetics of DC-activated immune effector cells. The viable cells were counted with trypan blue staining at different time points 
after coculture and the growth curves of 5 samples are shown. (B) and (C) CD3, CD56, CD4 and CD8 phenotype analysis. The 
DC-activated cells from day 0, 12 and 19 were stained with antibodies against CD4, CD8, CD3 and CD56 and analyzed with 
flow cytometry. The percentages of different lymphocyte subsets were analyzed and shown in bar graphs. Donor 1*, PBMC 
collected at a different time point from donor 1.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Memory and effector T cell analyses of DC-activated immune effector cells Figure 7
Memory and effector T cell analyses of DC-activated immune effector cells. (A) & (B) Memory and effector pheno-
type analysis of a CD4 dominant donor (A) and a CD8 dominant donor (B). The DC-activated cells from day 0, 12, and 17 after 
coculture were analyzed for CD3, CD4, CD8, CD27, CD28, CD45RA, and CCR7 using a seven-color panel of fluorochrome-
labeled Ab with FACSAria. The cells were gated for CD3 and CD4 or CD8 as total cells for the percentage analysis. One rep-
resentative flow graph of 5 performed experiments is presented.Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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Figure 8 (see legend on next page)Journal of Hematology & Oncology 2009, 2:34 http://www.jhoonline.org/content/2/1/34
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analyses including IFN-γ release and cytotoxicity assays
suggest that the DC-activated cells had lower activities
than the expanded IFN-γ effector cells.
Discussion
Adoptive immune cell therapy has shown great promise
in treating viral diseases and melanoma. [2,6] Continued
efforts are focused on the generation of sufficient amount
of antigen-specific immune cells and optimal condition-
ing of immune homeostasis in patients in order to achieve
a sustained in vivo immune surveillance. [24-26] Here, we
compared three ex vivo immune cell preparation protocols
and phenotypically and functionally characterized these
cells. The rapid protocols based on IFN-γ and CD137
selection generate a small number of antigen-specific
effector cells with high percentage of central memory T
cells in a very short period of time. The DC-activation pro-
tocol generates more immune cells, albeit, with more dif-
ferentiated phenotype and reduced proportion of antigen-
specific effector cells.
Based on analyses of a large number of donors, we found
that individual response to a given antigen could be either
CD4- or CD8-dominant, which is antigen- and donor-
dependent. Immune effector cells isolated based on IFN-γ
expression displayed a CD4 or CD8 bias consistent with
the donor's immune dominance. However, antigen-spe-
cific CD137 positive cells showed a higher ratio of CD4
effector cells regardless of the subject's immune pheno-
type; this is in contrast to previous reports that emphasize
the induction of CD8 effector cells after CD137 enrich-
ment. [15,22,27] We did, however, show that CD8 T cells
displayed higher density of CD137 than did CD4 T cells.
It is well documented that CD137 costimulation pro-
motes both CD4 and CD8 T cell expansion and long term
memory. [28-30] Our finding that more CD4 T cells than
CD8 T cells are detected in the CD137-positive cell popu-
lation suggests a rapid induction of CD137 in the memory
T helper repertoire immediately after antigen stimulation.
Although the enriched CD137 immune cells contained a
higher CD4 T cell ratio, further expansion in culture
restored the donor's original dominant phenotype, with a
higher CD3-CD56+ NK cell population than those found
in the expanded IFN-γ enriched immune cells (Fig. 3A).
This result suggests that IFN-γ is a more restricted adoptive
immune response marker and represent less of an innate
immune marker as does CD137.
The  ex vivo DC-activation protocol generated different
ratios of CD4, CD8 and NK cells in culture, which again,
appeared to be donor-dependent. Whether the immune
dominance has any effect on in vivo efficacy of the cul-
tured immune effector cells awaits further investigation.
As CD4 T cells are important for the maintenance of long-
term anti-viral CD8 T cell memory [31], therapeutic
immune cells should include polyclonal CD4 and CD8 T
cells. Both IFN-γ and CD137 selection approaches gener-
ated increased number of memory type of cells represent-
ative of polyclonal CD4 and CD8 T cells that may have
increased proliferation potential after infusion. Although
the antigen-specific memory T cells from PBMC may be
low; for examples, the average yield of LMP2A-specific
IFN-γ positive immune effector cells from healthy EBV-
seropositive donors is only 0.22 ± 0.13% (n = 6, after two
rounds of affinity column purification), they can be
expanded to more than two orders of magnitude in cul-
ture in two weeks and maintain their high antigen specif-
icity.
It is evident that the LMP2A pentadecapeptides efficiently
activate both CD4 and CD8 T cells in a short exposure
period (3–13 hr). This was surprising since CD8 T cells are
activated through class I MHC loaded with short 9–11
amino acid peptide epitopes, different from CD4 T cells,
which are activated through class II MHC loaded with 12–
15 amino acid peptide epitopes. The pentadecapeptide
antigens apparently activated CD8 T cells with high effi-
ciency through cross-presentation. This has been con-
firmed with various pentadecapeptide antigens
(unpublished). The processing of class II MHC peptides
into class I epitopes for cross-presentation to CD8 T cells
appears to be highly efficient with both the IFN-γ and the
CD137 protocols, as with the DC-activation method. The
Functional analyses of DC-activated and ex vivo expanded immune effector cells Figure 8 (see previous page)
Functional analyses of DC-activated and ex vivo expanded immune effector cells. EBV LMP2A-specific effector cells 
were generated by stimulation of non-adherent PBMC with DC pulsed with LMP2A pentadecapeptides. (A) Analysis of antigen-
specific effector cytokines and CD107a expression. The DC-activated immune cells from day 19 coculture were stimulated 
with autologous DC pulsed with LMP2A peptides, WT1 peptides (non-specific control) or no stimulation (IE cell alone) for 6 
hours. The cells were stained with Ab against CD4, CD8, CD107a and IFN-γ. Flow cytometry analyses of IL-2, IFN-γ and 
CD107a-positive cells in CD4-gated or CD8-gated populations were illustrated as representative of five experiments. (B) 
Comparison of cytolytic function of IFN-γ-selected (same donor as in Fig. 4C) versus DC-activated LMP2-specific immune 
effector cells. The LMP2A-specific effector cells were mixed with target cells including autologous BLCL, DC-LMP2A, or con-
trol DC-WT1 at 1:1 ratio and analyzed for cytolytic activity based on the CFSE-labeling method as described in Materials and 
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detailed molecular mechanism of the efficient cross-pres-
entation requires further investigation.
To assess differentiation and maturation status of the ex
vivo generated T cells, we applied multi-color flow cytom-
etry to detect differentiation and homeostatic marker
CD45RA, trafficking marker CCR7, and costimulatory
marker CD27 and CD28. [32,33] It is not surprising that
both the IFN-γ- and the CD137-enriched antigen-specific
effector cells displayed more memory markers than did
the DC coculture-expanded cells. While preserving Tcm
cells is critical to in vivo therapeutic efficacy,[7,34,35] clin-
ical studies have proven that ex vivo expanded effector cells
can persist many years after infusion. [36] Clinical bene-
fits of these different protocols will require detailed evalu-
ation in a large cohort of patients.
The differentiation status of the ex vivo generated immune
cells may contribute to their in vivo therapeutic efficacy.
Homeostasis of antigen-specific memory cells can vary
depending on antigen source, the immune milieu and
individual donor. It is known that Tcm cells are mainly
located in lymphoid tissues and Tem cells are distributed
in diverse non-lymphoid sites including lung, liver and
intestine. [37] In addition, bone marrow has been shown
to embrace increased number of anti-cancer or anti-virus
memory T cells. [38-40] After ex vivo expansion, however,
wherever the T cells come from, they tend to bestow
exhausted proliferation and replicative senescence associ-
ated with down-regulation of anti-apoptotic protein Bcl-2
and Bcl-xL, and decreased telomere length. [33,34,41]
Modification of antigen presentation protocol and culture
condition may help overcome the immune cell exhaus-
tion problem. [9,42]
For patients with acute infections or illness, direct isola-
tion of antigen-specific immune cells from partly HLA-
matched healthy donors represents an attractive emer-
gency approach to obtain therapeutic cells. [43,44] This
approach offers several advantages including a shortened
handling time and increased proliferation potential in
vivo. Although the number of immune cells is limited with
the direct isolation approach, clinical evidence supports
that only a small number of such immune cells, in the
range of 103-104/kg body weight, is sufficient to attain
therapeutic efficacy in transplant patients. [13,45,46]Ex
vivo expansion of immune cells, nevertheless, may be nec-
essary for patients with a compromised immunity.
[47,48]
Conclusion
The two rapid immune cell isolation methods generate
functional effector cells in less than 24–48 hr suitable for
emergency immune cell preparation. On the other hand,
the DC-activation method expands antigen-specific
immune effector cells while effectively reduce the number
of non-specific cells. Depending on clinical needs, for
examples, the urgency for treatment, patient's body
weight (e.g. less cells are needed for pediatric patients), or
patient's immune cell proliferative potential in vivo, the
method of immune cell preparation may differ. Our data
indicate that IFN-γ selection followed by ex vivo expansion
represents the best approach for the generation of high
amount of antigen-specific immune effector cells. Further
efforts to overcome immune tolerance and expand anti-
gen-specific immune cells with prolonged in vivo persist-
ence are critical to the success of immune cell therapy.
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